Catalyst Dossier · compiled by CeliA 🧫

MESOBLAST LTD (MESO)

Biotechnology · market cap $18.4B · as of 2026-06-25

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Mesoblast Ltd (MESO) is an Australian cell therapy biotech with 81 employees and a market cap of approximately $18.4B at ~$15.55/share, built around a platform of allogeneic mesenchymal stem/precursor cell therapies. Its most advanced assets include rexlemestrocel-L in Phase 3 for degenerative disc disease and remestemcel-L in Phase 3 for acute graft-versus-host disease (aGVHD), alongside a broad but data-sparse pipeline spanning Crohn's disease, chronic heart failure, and other inflammatory and degenerative indications. No upcoming catalysts are calendared and no recent catalysts have been disclosed.

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
Rexlemestrocel-L	Phase 3	Degenerative Disc Disease
Single Dose MPCs Injection	Phase 2	Degenerative Disc Disease
adult human mesenchymal stem cells	Phase 3	Crohn's Disease
Prochymal®	Phase 3	Graft Versus Host Disease
MSB-CAR001 Combined With Hyaluronan	Phase 2	Anterior Cruciate Ligament Injury
remestemcel-L	Phase 3	Grade B aGVHD
Mesenchymal Precursor Cells (MPCs)	Phase 2	Diabetic Nephropathy
NeoFuse	Phase 2	Cervical Degenerative Disc Disease
Allogeneic Mesenchymal Precursor Cells	Phase 2	Rheumatoid Arthritis
Mesenchymal Precursor Cells (MPC) 12.5 M	Phase 2	Acute Myocardial Infarction
PROCHYMAL adult human mesenchymal stem cells	Phase 3	Crohn's Disease
Prochymal™ adult human mesenchymal stem cells	Phase 2	Crohn's Disease
Infusion of one MPC expanded cord unit and one unexpanded cord unit	Phase 3	Acute Myelogenous Leukemia
Prochymal® - 2 Million cells/kg	Phase 2	Graft Vs Host Disease
Allogeneic Mesenchymal Precursor Cells (MPCs)	Phase 3	Chronic Heart Failure
Prochymal	Phase 2	Graft Versus Host Disease
Lumbar Interbody Fusion with Autograft	Phase 2	Degenerative Disc Disease
Prochymal™	Phase 2	Pulmonary Disease, Chronic Obstructive
Rexlemestrocel-L + HA mixture	Phase 3	Degenerative Disc Disease
Mesenchymal Stem Cells	Phase 2	Recovery Following Partial Medial Meniscectomy

Price & technical context

3-month

-24.6%

6-month

-17.6%

12-month

+2.5%

52-wk range

$10.03–$20.96

vs 50-day MA

-15.8%

vs 200-day MA

-11.2%

Realized vol

66.0%

Max drawdown

-52.3%

Daily closes through 2026-03-23. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for MESO (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.